158 related articles for article (PubMed ID: 32740717)
1. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
2. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
[TBL] [Abstract][Full Text] [Related]
3. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
4. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
5. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
7. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
8. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
9. Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Lavolé A; Danel S; Baudrin L; Gounant V; Ruppert AM; Epaud C; Belmont L; Rosencher L; Cadranel J; Milleron B
Bull Cancer; 2012 Apr; 99(4):E43-8. PubMed ID: 22450449
[TBL] [Abstract][Full Text] [Related]
10. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
[TBL] [Abstract][Full Text] [Related]
11. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
12. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.
Miyoshi T; Hayashi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C; Nakano T; Egawa T
Support Care Cancer; 2022 Apr; 30(4):3345-3351. PubMed ID: 34984552
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
14. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
[TBL] [Abstract][Full Text] [Related]
15. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
[TBL] [Abstract][Full Text] [Related]
16. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
[TBL] [Abstract][Full Text] [Related]
17. Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
Yamamoto Y; Watanabe K; Tsukiyama I; Matsushita H; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2015 Apr; 35(4):2199-204. PubMed ID: 25862878
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
19. Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial.
Horinouchi H; Kubota K; Miyanaga A; Nakamichi S; Seike M; Gemma A; Yamane Y; Kurimoto F; Sakai H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T; Ohe Y
ESMO Open; 2018; 3(1):e000288. PubMed ID: 29503734
[TBL] [Abstract][Full Text] [Related]
20. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
